Effectiveness of Oral Semaglutide Versus Injectable Dulaglutide in Adults With Type 2 Diabetes and Obesity: A Single-Centre Experience
https://doi.org/10.15605/jafes.041.S1
- Author:
Nur Shairah Binti Mohamad Fazial
1
;
Raja Yunalis Binti Raja Iskandar
1
;
Nur Syuhaida Binti Noorazam
1
;
Saiful Shahrizal Bin Shudim
1
Author Information
1. Hospital Sultan Haji Ahmad Shah
- Publication Type:Journal Article
- MeSH:
Adult;
dulaglutide;
semaglutide;
Diabetes Mellitus, Type 2;
Obesity
- From:
Journal of the ASEAN Federation of Endocrine Societies
2026;41(S1):43-
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are
increasingly used in the management of type 2 diabetes
mellitus (T2DM) and obesity because of their glucoselowering and weight reduction benefits. However, realworld outcomes may differ from clinical trial data.
Methodology:This retrospective cohort study included adults with T2DM
and obesity initiated on oral semaglutide or injectable
dulaglutide at Hospital Sultan Haji Ahmad Shah between
2023 and 2025. Baseline and approximately 6-month
follow-up data were obtained from electronic medical
records. Outcomes included weight, body mass index
(BMI), glycated hemoglobin A1c (HbA1c), total daily
insulin dose (TDD), low-density lipoprotein (LDL), and
gastrointestinal adverse effects. Results are presented as
median (interquartile range, IQR).
Results:A total of 22 patients were included, with a median age of
45 years (IQR 39.3–54.5); 13 (59.1%) were male. Thirteen
patients (59.1%) received oral semaglutide and nine (40.9%)
received injectable dulaglutide. In the semaglutide group,
median HbA1c changed from 8.1% (7.4–9.1) to 8.2% (7.1–
9.3), weight from 95.4 kg (84.0–99.1) to 89.6 kg (79.0–100.0),
BMI from 33.9 kg/m² (31.4–40.8) to 33.6 kg/m² (31.2–35.6),
TDD from 64 IU/day (20–82) to 46 IU/day (18–48), and
LDL from 2.2 mmol/L (1.6–2.3) to 2.3 mmol/L (1.3–3.0).
In the dulaglutide group, median HbA1c improved from
7.6% (7.4–9.6) to 6.9% (6.5–8.4), weight from 117.0 kg
(101.0–121.0) to 111.0 kg (105.0–119.0), BMI from 41.0 kg/
m² (40.0–49.0) to 42.5 kg/m² (38.0–48.0), TDD from 33 IU/
day (30.5–34.0) to 34 IU/day (30.5–34.0), and LDL from 2.2
mmol/L (1.8–2.9) to 2.6 mmol/L (2.0–4.0). Gastrointestinal
side effects occurred in 4/13 (30.8%) oral semaglutide users
and 0/9 dulaglutide users.
Conclusion:Injectable dulaglutide showed greater improvement in
HbA1c, while both groups demonstrated variable effects
on weight, BMI, insulin requirement, and LDL in routine
practice.
- Full text:202607291740463950EP_A043.pdf
